Magdalena Å**š**viderska

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6016595/publications.pdf

Version: 2024-02-01

		623734	642732
34	555	14	23
papers	citations	h-index	g-index
35	35	35	1148
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Blood bioactive sphingolipids in patients with advanced serous epithelial ovarian cancer – mass spectrometry analysis. Archives of Medical Science, 2021, 17, 53-61.	0.9	2
2	High prevalence of anti-HEV antibodies among patients with immunosuppression and hepatic disorders in eastern Poland. Archives of Medical Science, 2021, 17, 675-681.	0.9	3
3	Brain-derived neurotrophic factor as a potential diagnostic marker in minimal hepatic encephalopathy. Clinical and Experimental Hepatology, 2021, 7, 117-124.	1.3	4
4	Lp-PLA2 as a promising predictor of comorbidities in patients with severe psoriasis. Journal of Dermatological Treatment, 2020, 31, 524-530.	2.2	4
5	High CD163 Expression on Classical Monocytes Is Associated with Immune Control of HBV Infection in Noncirrhotic Patients. Mediators of Inflammation, 2020, 2020, 1-13.	3.0	17
6	Serum Concentrations of Th17-Associated Interleukins and Autoimmune Phenomena are Associated with the Degree of Liver Damage in Alcoholic Liver Disease. Journal of Gastrointestinal and Liver Diseases, 2020, 26, 269-274.	0.9	11
7	Clinical Usefulness of the Inhibitory Control Test (ICT) in the Diagnosis of Minimal Hepatic Encephalopathy. International Journal of Environmental Research and Public Health, 2020, 17, 3645.	2.6	5
8	Adipocyte Fatty Acidâ€Binding Protein as a Novel Marker of Psoriasis and Clinical Response to Acitretin. Lipids, 2019, 54, 445-452.	1.7	6
9	Oxidative stress biomarkers in the serum and plasma of patients with non-alcoholic fatty liver disease (NAFLD). Can plasma AGE be a marker of NAFLD? Oxidative stress biomarkers in NAFLD patients. Free Radical Research, 2019, 53, 841-850.	3.3	73
10	Unique Roles of Sphingolipids in Selected Malignant and Nonmalignant Lesions of Female Reproductive System. BioMed Research International, 2019, 2019, 1-7.	1.9	8
11	Liver fatty acid-binding protein might be a predictive marker of clinical response to systemic treatment in psoriasis. Archives of Dermatological Research, 2019, 311, 389-397.	1.9	9
12	Chronic hepatitis B virus infection is associated with decreased serum 25(OH)D concentration in non-cirrhotic patients. Clinical and Experimental Hepatology, 2019, 5, 75-80.	1.3	6
13	Free Radical Production, Inflammation and Apoptosis in Patients Treated With Titanium Mandibular Fixations—An Observational Study. Frontiers in Immunology, 2019, 10, 2662.	4.8	36
14	Serum YKL-40 as a potential biomarker of inflammation in psoriasis. Journal of Dermatological Treatment, 2018, 29, 19-23.	2.2	15
15	Activity of alcohol dehydrogenase isoenzymes and aldehyde dehydrogenase in sera of patients with hepatitis C. Archives of Medical Science, 2018, 14, 281-287.	0.9	17
16	Effect of psoriasis activity and topical treatment on serum lipocalin-2 levels. Journal of Dermatological Treatment, 2017, 28, 136-140.	2.2	14
17	Serum Fatty Acidâ€Binding Protein 4 is Increased in Patients with Psoriasis. Lipids, 2017, 52, 51-60.	1.7	21
18	Plasma and ovarian tissue sphingolipids profiling in patients with advanced ovarian cancer. Gynecologic Oncology, 2017, 147, 139-144.	1.4	35

#	Article	IF	Citations
19	Serum irisin levels in patients with psoriasis. Journal of Dermatological Treatment, 2017, 28, 304-308.	2.2	18
20	The interplay between Th17 and T-regulatory responses as well as adipokines in the progression of non-alcoholic fatty liver disease. Clinical and Experimental Hepatology, 2017, 3, 127-134.	1.3	20
21	Serum Cytokeratin 18 M30 Levels in Chronic Hepatitis B Reflect Both Phase and Histological Activities of Disease. Mediators of Inflammation, 2017, 2017, 1-8.	3.0	9
22	High serum N-terminal propeptide of procollagen type III concentration is associated with liver diseases. Przeglad Gastroenterologiczny, 2017, 3, 203-207.	0.7	5
23	Changed Profile of Serum Transferrin Isoforms in Liver Diseases. Clinical Laboratory, 2017, 63, 349-354.	0.5	8
24	Simple non-invasive markers for early diagnosis and determination of the severity of liver diseases. Clinical and Experimental Hepatology, 2016, 4, 149-154.	1.3	1
25	The occurrence of autoantibodies in patients with chronic HCV infection, including patients dialyzed and after kidney transplantation. Clinical and Experimental Hepatology, 2016, 4, 161-166.	1.3	5
26	Hyaluronic acid concentration in liver diseases. Clinical and Experimental Medicine, 2016, 16, 523-528.	3.6	35
27	Selected Noninvasive Markers in Diagnosing Liver Diseases. Laboratory Medicine, 2016, 47, 67-72.	1.2	1
28	The effect of topical treatment and psoriasis severity on serum retinol-binding protein-4 levels. Journal of Dermatological Treatment, 2016, 27, 114-119.	2.2	8
29	Serum Alcohol Dehydrogenase and Aldehyde Dehydrogenase Activity in the Course of Hepatitis C. Clinical Laboratory, 2016, 62, 2155-2159.	0.5	1
30	Original article Distribution of HBV genotypes in Poland. Clinical and Experimental Hepatology, 2015, 1, 1-4.	1.3	9
31	Effect of psoriasis activity on serum adiponectin and leptin levels. Postepy Dermatologii I Alergologii, 2015, 2, 101-106.	0.9	43
32	Serum adiponectin and leptin levels in psoriatic patients according to topical treatment. Journal of Dermatological Treatment, 2015, 26, 134-138.	2.2	21
33	Review The diagnostics of colorectal cancer. Wspolczesna Onkologia, 2014, 1, 1-6.	1.4	57
34	Serum cytochrome c and m30â€neoepitope of cytokeratinâ€18 in chronic hepatitis C. Liver International, 2014, 34, 544-550.	3.9	27